查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2000719

急性骨髓性白血病治疗市场：2026年至2032年全球预测（依治疗方法、作用机制、治疗阶段、给药途径、患者年龄及最终用户划分）

Acute Myeloid Leukemia Therapeutics Market by Therapy Type, Mechanism Of Action, Line Of Therapy, Route Of Administration, Patient Age, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，急性骨髓性白血病治疗市场价值将达到 11.2 亿美元，到 2026 年将成长至 12.5 亿美元，到 2032 年将达到 26.1 亿美元，年复合成长率为 12.74%。

主要市场统计数据
基准年 2025 11.2亿美元
预计年份：2026年 12.5亿美元
预测年份：2032年 26.1亿美元
复合年增长率 (%) 12.74%

对急性骨髓性白血病治疗的发展历程进行了简明扼要的基础性概述，重点在于临床复杂性、精准医疗方法和商业性需求。

急性骨髓性白血病(AML) 仍然是临床上最复杂的骨髓恶性肿瘤之一，其特征是遗传因素多样、患者群体异质性高以及治疗模式不断演变。过去十年，治疗模式已从广谱细胞毒性疗法转向精准标靶治疗和免疫肿瘤疗法。这项转变的驱动力在于对分子层面疾病认识的加深、诊断分层技术的改进以及先进生技药品和细胞疗法的成熟。因此，研究、临床实践和商业领域的各方相关人员面临着一个快速变化的环境，需要采取适应性策略。

权威地检验了科学、监管和商业领域中正在重塑急性骨髓性白血病。

急性髓性白血病（AML）的治疗格局正经历着一场变革，这主要得益于科学进步、监管政策的演变以及商业性创新。基因组分析和微量残存疾病（MRD）检测使得患者筛选更加精准，治疗策略也更加灵活，精准医疗正从概念走向日常临床实践。抗体药物偶联物（ADC）和融合蛋白等生技药品平台的成熟进一步推动了这一转变，这些平台拓宽了治疗指数，并实现了靶向细胞毒性药物的递送。同时，细胞疗法的研发和规模化生产虽然有望带来持续的疗效，但也对生产和物流提出了独特的要求。

对贸易政策的累积影响进行清晰分析，以评估其对供应链、製造业投资选择以及 2025 年获得抗逆转录病毒疗法等方面的影响。

2025年关税的引入和贸易政策的转变对整个急性髓系白血病（AML）治疗价值链产生了切实的连锁反应，其累积影响主要体现在供应链韧性、生产策略和患者负担成本趋势等方面。对于生技药品和细胞疗法生产中依赖进口的组件，例如特种试剂、一次性系统和关键设备，采购模式发生了变化，迫使製造商和合约合作伙伴重新评估采购区域和库存缓衝。为此，多个相关人员加快了近岸外包的步伐，并使其供应商网路多元化，以减轻关税相关干扰的影响。

全面的細項分析揭示了治疗方法类型、作用机制、临床环境、给药途径和患者人口统计特征如何决定临床和商业策略。

细分市场分析揭示了每种治疗方法类型、作用机制、治疗线、最终用户、给药途径和患者年龄组的不同机会和运作要求。治疗方式选择包括多种小分子化合物，例如抗体药物偶联物、融合蛋白和单株抗体等生技药品；细胞疗法，包括CAR-T疗法和干细胞移植；基因疗法；以及BCL-2抑制剂、 DNA甲基转移酵素抑制剂和蛋白酪氨酸激酶抑制剂（进一步细分为FLT3和KIT标靶药物）。这些治疗方法的差异对临床实验室设计、生产复杂性和核准后证据产生等方面都有不同的影响。

详细的区域观点突显了全球主要市场在采用驱动因素、监管预期和营运重点方面的差异。

区域洞察凸显了美洲、欧洲、中东和非洲以及亚太地区在应用驱动因素、监管预期和营运重点方面的差异，这些差异各自以独特的方式影响临床开发和商业化。在美洲，分散的支付方环境和复杂的报销机制，加上强大的临床实验室网络和成熟的肿瘤中心，使得证据生成和价值论证对于高端产品的获取和推广至关重要。在欧洲、中东和非洲，集中式的法规结构和不断变化的报销标准进一步凸显了健康技术评估 (HTA) 合规性和区域定价策略的重要性。

此方法将科学差异化与以生产规模和支付方为重点的证据产生相结合，从而加强了企业的策略行动和竞争合作。

急性髓系白血病（AML）治疗生态系统中的主要企业正在寻求将深厚的科学差异化优势与切实可行的商业计划相结合的策略。大型製药企业正利用其成熟的商业基础设施和全球开发经验，加速后期临床开发项目，同时确保与支付方儘早建立联繫。中型生物技术公司和专业细胞疗法公司则专注于敏捷创新，瞄准分子定义的亚群，并寻求策略合作伙伴关係，以弥补生产能力和全球市场准入方面的差距。在整个产业中，企业正越来越多地建立合作伙伴关係，将独特的平台与互补的资产结合，以降低临床开发风险并扩大复杂生产流程的规模。

为协调临床开发、生产韧性和支付方参与，以加速提高医疗服务可近性和商业性成功，提出切实可行的策略建议。

产业领导企业应采取一系列切实可行且影响深远的措施，使研发重点与商业化实际情况相符，同时确保供应链的连续性和与支付方的良好关係。首先，优先发展以生物标记主导的临床管道和适应性测试设计，以降低后期研发风险，并提高获得监管部门核准和报销的可能性。其次，加速供应商网路多元化，并考虑区域性生产投资，以减少贸易中断带来的影响，缩短病患用药时间。第三，从研发规划的早期阶段就纳入健康经济学和结果研究，以产生基于价值的合约所需的真实世界数据（REW），并支持差异化定价谈判。

为了确保研究结果的可靠性，我们采用了一种透明且严谨的混合方法研究方法，结合了对专家的初步访谈、二手文献综述和证据检验验证。

本研究采用多层次、可重复的方法，结合定性和定量方法，以确保检验的稳健性和三角验证。主要调查包括对临床医生、临床检验医师、支付方和行业高管进行结构化访谈，以了解临床实践、报销趋势和营运限制等方面的实际观点。专家咨询为供应链中断和监管变化的情境分析提供了见解，而医生主导的实验室审查则揭示了真实的治疗模式和仿单标示外用药的背景资讯。

一份简洁、综合的总结，强调了临床、製造和商业策略之间需要协调，才能对病人产生持久的影响。

总之，目前急性髓系白血病（AML）治疗的特点是科学创新加速发展、监管机构和支付方的期望不断变化以及运营复杂性日益增加，所有这些因素共同重塑了患者的就医管道。成功需要一项整合策略，将分子标靶临床开发与强大的生产基础设施、符合支付方要求的证据生成以及本地化优化的商业化计划相结合。积极应对供应链漏洞、采用适应性临床实验室设计并儘早与支付方沟通的相关人员，更有能力将治疗进展转化为可持续的临床和商业性成果。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：急性骨髓性白血病治疗市场：依治疗方法

  • 生技药品
    • 抗体-药物偶联物
    • 融合蛋白
    • 单株抗体
  • 细胞疗法
    • CAR-T细胞疗法
    • 干细胞移植
  • 基因治疗
  • 低分子化合物

第九章：急性骨髓性白血病治疗市场：依作用机转划分

  • BCL-2抑制剂
  • DNA甲基转移酵素酶抑制剂
  • HDAC抑制剂
  • 免疫调节剂
  • 蛋白酪氨酸激酶抑制剂

第十章：急性骨髓性白血病治疗市场：依治疗阶段划分

  • 第 1 行
  • 第二行
  • 从第三行开始

第十一章：急性骨髓性白血病治疗市场：依给药途径划分

  • 静脉
  • 口服
  • 皮下

第十二章：急性骨髓性白血病治疗市场：依患者年龄组别划分

  • 成人
  • 老年人
  • 儿童

第十三章：急性骨髓性白血病治疗市场：依最终用户划分

  • 医院药房
  • 零售药房
  • 专科诊所

第十四章：急性骨髓性白血病治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：急性骨髓性白血病治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：急性骨髓性白血病治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国急性骨髓性白血病治疗市场

第十八章：中国急性骨髓性白血病治疗市场。

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Actinium Pharmaceuticals, Inc.
  • Agios Pharmaceuticals, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Astex Pharmaceuticals, Inc.（Otsuka Group）
  • Celgene Corporation
  • CTI BioPharma Corp.
  • Cyclacel Pharmaceuticals, Inc.
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Janssen Global Services, LLC
  • Jazz Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • MEI Pharma, Inc.
  • Merck & Co., Inc.
  • Merus NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • The Bristol Myers Squibb Company
Product Code: MRR-02026C4C8B97

The Acute Myeloid Leukemia Therapeutics Market was valued at USD 1.12 billion in 2025 and is projected to grow to USD 1.25 billion in 2026, with a CAGR of 12.74%, reaching USD 2.61 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.12 billion
Estimated Year [2026] USD 1.25 billion
Forecast Year [2032] USD 2.61 billion
CAGR (%) 12.74%

A concise foundational overview of acute myeloid leukemia therapeutic evolution highlighting clinical complexity, precision approaches, and commercial imperatives

Acute myeloid leukemia (AML) remains one of the most clinically complex hematologic malignancies, characterized by heterogeneous genetic drivers, variable patient demographics, and evolving therapeutic paradigms. Over the past decade, the therapeutic landscape has shifted from broadly cytotoxic regimens toward precision-targeted approaches and immuno-oncology modalities. This transition has been driven by deeper molecular understanding, improved diagnostic stratification, and maturation of advanced biologics and cellular therapies. Consequently, stakeholders across research, clinical practice, and commercial functions face a rapidly changing environment that demands adaptive strategies.

Clinicians now balance established induction-maintenance frameworks with an expanding armamentarium of targeted inhibitors, epigenetic modulators, and cell-based interventions. At the same time, payers and provider systems are adapting reimbursement approaches to account for high-cost one-time therapies and long-term outcomes. These dynamics create both opportunities and operational complexities for manufacturers, contract development and manufacturing organizations, and supply-chain partners. Therefore, a clear, actionable synthesis of clinical trends, regulatory shifts, and commercial imperatives is essential for leaders making investment, alliance, and launch decisions in the AML therapeutics arena.

An authoritative examination of the converging scientific, regulatory, and commercial forces reshaping acute myeloid leukemia therapy development and access

The AML therapeutic landscape is experiencing transformative shifts driven by converging scientific advances, regulatory evolution, and commercial innovation. Precision medicine has moved from concept to clinical routine as genomic profiling and minimal residual disease assays enable more refined patient selection and adaptive treatment strategies. This shift is complemented by the maturation of biologic platforms, including antibody drug conjugates and fusion proteins, that extend the therapeutic index and permit targeted cytotoxic delivery. Simultaneously, the development and scaling of cell therapies have introduced durable response potential while imposing unique manufacturing and logistics requirements.

Concurrently, regulatory pathways are evolving to accommodate novel modalities and surrogate endpoints, which accelerates time-to-access but also raises evidentiary demands for long-term safety and real-world effectiveness. Payers are responding with value-based contracting pilots and outcomes-based reimbursement models that link upfront cost to durability of response. Industry partnerships are proliferating to pool expertise across discovery, translational science, and commercial access, altering traditional competitive dynamics. As a result, success increasingly depends on integrated strategies that align clinical development with supply-chain readiness and payer engagement, rather than isolated product-centered plans.

A clear analysis of cumulative trade policy impacts on AML therapeutic supply chains, manufacturing investment choices, and access considerations in 2025

The introduction of elevated tariff regimes and trade policy shifts in 2025 created tangible ripple effects across the AML therapeutics value chain, with cumulative impacts centering on supply-chain resilience, manufacturing strategy, and cost-to-patient dynamics. Import-dependent components used in biologics and cell therapy manufacturing, including specialized reagents, single-use systems, and critical equipment, saw altered procurement profiles that prompted manufacturers and contract partners to reassess sourcing geographies and inventory buffers. In response, several stakeholders accelerated nearshoring initiatives and diversified supplier networks to mitigate exposure to tariff-related disruptions.

Beyond procurement, tariffs influenced capital expenditure decisions for new manufacturing capacity, particularly for complex modalities that require specialized clean-room facilities and cold-chain infrastructure. Firms contemplating new plants weighed increased import duties on equipment and spare parts against long-term strategic imperatives for regional supply security. Moreover, higher landed costs for imported materials exerted pressure on pricing negotiations and distributor agreements, which in turn affected hospital and specialty clinic budgets for oncology therapeutics. These pressures reinforced the need for transparent cost-of-goods analyses and collaborative contracting mechanisms between manufacturers and payers.

Finally, tariffs intensified the focus on regulatory and customs harmonization to reduce administrative delays that compound the financial impact of trade measures. Stakeholders increasingly sought engagement with policymakers and industry associations to clarify tariff classifications for biologic and advanced therapy components, and to advocate for exemptions where national health priorities justified rapid access. As a consequence, companies that proactively adapted procurement strategies, reinforced regional manufacturing footprints, and engaged constructively with policymakers were better positioned to preserve supply continuity and protect patient access amid the changing trade environment.

Comprehensive segmentation analysis revealing how therapy modality, mechanism, care setting, administration route, and patient demographics define clinical and commercial strategies

Segmentation insights reveal differentiated opportunities and operational demands across therapy types, mechanisms, lines of therapy, end users, routes of administration, and patient age cohorts. Therapeutic modality choices span biologic options such as antibody drug conjugates, fusion proteins, and monoclonal antibodies; cell therapies including CAR T approaches and stem cell transplantation; gene therapies; and a range of small molecules where BCL-2 inhibitors, DNA methyltransferase inhibitors, and tyrosine kinase inhibitors, with further subdivision into FLT3 and KIT targeted agents, play a central role. These modality distinctions carry distinct implications for clinical trial design, manufacturing complexity, and post-approval evidence generation.

Mechanism-focused segmentation underscores how BCL-2 inhibition, epigenetic modulation via DNA methyltransferase inhibitors, histone deacetylase modulation, immunomodulatory agents, and tyrosine kinase inhibition differentially influence combination strategies and resistance management. In terms of line of therapy, first-line paradigms prioritize durability and tolerability in newly diagnosed populations, second-line treatments emphasize salvage efficacy and safety, and third-line and beyond options concentrate on overcoming acquired resistance and managing cumulative toxicity. End-user segmentation highlights that hospital pharmacies must coordinate inpatient administration and cold-chain storage for complex biologics, retail pharmacies navigate outpatient dispensing of oral regimens, and specialty clinics deliver advanced cellular therapies under highly controlled conditions.

Route-of-administration segmentation differentiates intravenous therapies that demand infusion infrastructure and monitoring from oral agents that enable at-home dosing but require adherence support, while subcutaneous options can reduce infusion burdens yet require patient education and administration training. Patient age segmentation shows that adult cohorts constitute the bulk of treatment decisions with geriatric populations often necessitating adapted dosing and comorbidity management, whereas pediatric cases require bespoke safety and developmental considerations. Integrating these segmentation lenses enables stakeholders to prioritize clinical development pathways, align manufacturing and distribution investments, and design differentiated market access approaches tailored to modality, mechanism, care setting, and patient demographics.

An in-depth regional perspective highlighting differentiated adoption drivers, regulatory expectations, and operational priorities across major global markets

Regional insights underscore divergent drivers of adoption, regulatory expectations, and operational priorities across the Americas, Europe Middle East and Africa, and Asia-Pacific regions, each presenting unique implications for clinical development and commercialization. In the Americas, fragmented payer landscapes and advanced reimbursement mechanisms coexist with robust clinical trial networks and established oncology centers, creating an environment where evidence generation and value demonstration are critical to premium access and uptake. Conversely, Europe Middle East and Africa encompasses a mix of centralized regulatory frameworks and variable reimbursement thresholds, which heightens the importance of health technology assessment alignment and regional pricing strategies.

Asia-Pacific presents accelerated adoption potential driven by large patient populations, growing diagnostic capabilities, and expanding manufacturing capacity, yet it also features diverse regulatory regimes and cost-sensitivity that necessitate regionalized clinical development plans and flexible commercial models. Across all regions, logistical considerations such as cold-chain robustness, local manufacturing partnerships, and expedited regulatory engagement materially affect launch sequencing and access timelines. Therefore, a regionally nuanced approach that balances centralized global coordination with local execution capacity will optimize patient reach and commercial sustainability.

Strategic company behaviors and competitive alignments that combine scientific differentiation with manufacturing scale and payer-focused evidence generation

Leading companies in the AML therapeutics ecosystem are pursuing strategies that blend deep scientific differentiation with pragmatic commercial planning. Large pharmaceutical organizations are leveraging established commercial infrastructure and global development expertise to accelerate late-stage programs and to secure payer conversations early. Mid-sized biotechs and specialized cell therapy firms focus on nimble innovation, targeting molecularly defined subpopulations and pursuing strategic collaborations to fill capability gaps in manufacturing and global access. Across the board, companies are increasingly forming alliances that combine proprietary platforms with complementary assets to de-risk clinical pathways and to scale complex manufacturing processes.

Manufacturing partners and contract development organizations are scaling capabilities for advanced modalities, investing in single-use technologies, closed-system cell processing, and decentralized fill-finish solutions to support faster patient access. At the same time, market entrants emphasize differentiated clinical trial designs that incorporate biomarker-driven enrollment and adaptive endpoints to generate compelling evidence for regulators and payers. Commercial playbooks reflect a shift toward value-based pricing discussions, outcomes tracking, and integrated service offerings that include diagnostics and patient support. Firms that integrate clinical innovation with supply-chain robustness and payer-aligned evidence generation maintain a competitive advantage in translating scientific promise into sustainable patient access.

Actionable strategic recommendations that align clinical development, manufacturing resilience, and payer engagement to accelerate access and commercial success

Industry leaders should pursue a set of pragmatic, high-impact actions that align R&D priorities with commercialization realities while safeguarding supply continuity and payer relationships. First, prioritize biomarker-driven clinical pathways and adaptive trial designs that de-risk late-stage development and enhance the probability of regulatory approval and reimbursement. Second, accelerate diversification of supplier networks and consider regional manufacturing investments to reduce exposure to trade-related disruptions and to shorten time-to-patient. Third, embed health economics and outcomes research early in development plans to generate the real-world evidence required for value-based contracting and to support differentiated pricing conversations.

Moreover, cultivate cross-sector partnerships that combine discovery platforms with manufacturing and distribution expertise to accelerate scale-up of complex modalities. Invest in digital tools for remote patient monitoring and adherence support, particularly for oral and subcutaneous therapies, to demonstrate real-world effectiveness and to support outcomes-based agreements. Finally, engage proactively with policymakers and payer stakeholders to clarify reimbursement pathways for one-time and high-cost therapies, and to advocate for regulatory harmonization that reduces administrative barriers to timely access. Collectively, these actions will strengthen resilience, expedite access, and align commercial expectations with clinical realities.

A transparent and rigorous mixed-methods research approach combining primary expert interviews, secondary literature review, and evidence triangulation to ensure dependable insights

The research methodology employed a layered and reproducible approach combining both qualitative and quantitative techniques to ensure robustness and triangulation of findings. Primary research included structured interviews with clinicians, clinical trial investigators, payers, and industry executives to capture frontline perspectives on clinical practice, reimbursement dynamics, and operational constraints. Expert consultations informed scenario analyses around supply-chain disruptions and regulatory shifts, while investigator-initiated study reviews provided context for real-world treatment patterns and off-label usage.

Secondary research encompassed a comprehensive review of peer-reviewed literature, clinical trial registries, regulatory guidances, and company disclosures to construct an evidence base for mechanism-specific efficacy and safety profiles. Commercial intelligence was derived from product labeling, conference proceedings, and public tenders to assess accessibility considerations across care settings. Data synthesis applied qualitative coding, comparative framework analysis, and cross-validation against multiple independent sources to reduce bias and to enhance credibility. Throughout, methodological transparency was maintained by documenting data provenance and by subjecting key assumptions to sensitivity checks and expert validation.

A concise integrative synthesis emphasizing coordinated clinical, manufacturing, and commercial strategies required to realize durable patient impact

In conclusion, the AML therapeutics landscape is characterized by accelerated scientific innovation, shifting regulatory and payer expectations, and evolving operational complexities that together redefine pathways to patient access. Success requires integrated strategies that pair molecularly targeted clinical development with resilient manufacturing, payer-aligned evidence generation, and regionally tailored commercialization plans. Stakeholders that proactively address supply-chain vulnerabilities, adopt adaptive clinical designs, and engage payers early will be better equipped to translate therapeutic advances into sustainable clinical and commercial outcomes.

Looking ahead, the intersection of precision diagnostics, advanced biologics, and cell therapies presents substantial promise for improving patient outcomes, provided that industry actors coordinate across scientific, regulatory, and commercial domains. By aligning investments in capability building with strategic partnerships and by embedding health-economic thinking throughout development programs, organizations can navigate complexity and deliver meaningful value to patients and healthcare systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Acute Myeloid Leukemia Therapeutics Market, by Therapy Type

  • 8.1. Biologic
    • 8.1.1. Antibody Drug Conjugates
    • 8.1.2. Fusion Proteins
    • 8.1.3. Monoclonal Antibodies
  • 8.2. Cell Therapy
    • 8.2.1. CAR T Cell Therapy
    • 8.2.2. Stem Cell Transplantation
  • 8.3. Gene Therapy
  • 8.4. Small Molecule

9. Acute Myeloid Leukemia Therapeutics Market, by Mechanism Of Action

  • 9.1. BCL-2 Inhibitors
  • 9.2. DNA Methyltransferase Inhibitors
  • 9.3. HDAC Inhibitors
  • 9.4. Immunomodulatory Agents
  • 9.5. Tyrosine Kinase Inhibitors

10. Acute Myeloid Leukemia Therapeutics Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Second Line
  • 10.3. Third Line And Beyond

11. Acute Myeloid Leukemia Therapeutics Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral
  • 11.3. Subcutaneous

12. Acute Myeloid Leukemia Therapeutics Market, by Patient Age

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Acute Myeloid Leukemia Therapeutics Market, by End User

  • 13.1. Hospital Pharmacy
  • 13.2. Retail Pharmacy
  • 13.3. Specialty Clinic

14. Acute Myeloid Leukemia Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Acute Myeloid Leukemia Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Acute Myeloid Leukemia Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Acute Myeloid Leukemia Therapeutics Market

18. China Acute Myeloid Leukemia Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Actinium Pharmaceuticals, Inc.
  • 19.7. Agios Pharmaceuticals, Inc.
  • 19.8. Amgen Inc.
  • 19.9. Astellas Pharma Inc.
  • 19.10. Astex Pharmaceuticals, Inc. by Otsuka Group
  • 19.11. Celgene Corporation
  • 19.12. CTI BioPharma Corp.
  • 19.13. Cyclacel Pharmaceuticals, Inc.
  • 19.14. Daiichi Sankyo Company, Limited
  • 19.15. Eisai Co., Ltd.
  • 19.16. F. Hoffmann-La Roche AG
  • 19.17. GlaxoSmithKline plc
  • 19.18. Janssen Global Services, LLC
  • 19.19. Jazz Pharmaceuticals PLC
  • 19.20. Johnson & Johnson Services, Inc.
  • 19.21. MEI Pharma, Inc.
  • 19.22. Merck & Co., Inc.
  • 19.23. Merus N.V.
  • 19.24. Novartis AG
  • 19.25. Pfizer Inc.
  • 19.26. Sanofi S.A.
  • 19.27. Sun Pharmaceutical Industries Ltd.
  • 19.28. Takeda Pharmaceutical Company Limited
  • 19.29. Teva Pharmaceutical Industries Ltd.
  • 19.30. The Bristol Myers Squibb Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BCL-2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DNA METHYLTRANSFERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HDAC INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 174. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 176. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 201. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 203. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 206. G7 ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 210. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 212. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 215. NATO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGIC, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)